drugset / Trial / NCT03194217
BEN-2001 in Parkinson Disease Patients With Excessive Daytime Sleepiness
RandomizedParallel-groupQuadruple-blindTreatment
Summary
This phase 2b study is designed as multicentre, multinational, randomized, double blind, parallel group and placebo controlled with three doses of Bavisant (0.5, 1, and 3 mg/d) in subjects with excessive daytime sleepiness with Parkinson's disease.
Timeline
- Start
- 2017-11-10
- Primary completion
- 2019-05-28
- Completion
- 2019-05-28
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | bavisant | Small molecule | 0.5 mg | Oral |
| Subject | bavisant | Small molecule | 1 mg | Oral |
| Subject | bavisant | Small molecule | 3 mg | Oral |